Blue Finessence
Blue Finessence
  • Home
  • About Us
  • Services
    • Our Services
    • Company Formation in Europe
  • News
    • Internal News
    • General news
  • Contact
  • Your cart is currently empty.

    Sub Total: $0.00 View cartCheckout

Monsanto Sues COVID-19 Vaccine Manufacturers, Alleging Copyright Infringement

Home / Finance / Monsanto Sues COVID-19 Vaccine Manufacturers, Alleging Copyright Infringement
Monsanto Sues COVID-19 Vaccine Manufacturers, Alleging Copyright Infringement
  • January 9, 2026
  • test
  • 32 Views

Monsanto Sues COVID-19 Vaccine Manufacturers, Alleging Copyright Infringement

Monsanto Sues COVID-19 Vaccine Manufacturers, Alleging Copyright Infringement

Authored by Zachary Stieber via The Epoch Times,

Bayer and its Monsanto division are suing COVID-19 vaccine manufacturers, alleging they used technology Monsanto developed and patented in the 1980s in their vaccines.

Bayer said in lawsuits that Pfizer, its partner BioNTech, and Moderna wrongly used technology Monsanto developed and used to make plants resistant to insects.

Pfizer-BioNTech and Moderna included the technology in their shots to enhance the stability of messenger ribonucleic acid (mRNA) “and thus the vaccines’ ability to confer immunity to the virus,” lawyers for Bayer and Monsanto said in the suits, which were filed on Jan. 6 with the U.S. court in Delaware.

Bayer was not involved in COVID-19 vaccine manufacturing or production.

Bayer said it was not seeking to interfere with the production of the COVID-19 vaccines, which are still being made and sold, but said the court should award it money, describing the defendants as having “profited handsomely from infringing vaccine sales worldwide.”

“Plaintiffs are entitled to damages as a result of Defendants’ infringement of the … Patent in an amount yet to be determined and adequate to compensate Plaintiffs for Defendants’ infringement, but in no event less than a reasonable royalty for the use made of the patented invention by Defendants, together with interest and costs as fixed by the Court,” with the exception of acts of infringement covered by one federal law, the filings state.

Pfizer, BioNTech, and Moderna earned billions of dollars from their vaccines against COVID-19 during the pandemic, according to company reports. Pfizer, for example, reported making $11.2 billion in 2023 from its shot.

“BioNTech is aware that Bayer and Monsanto have filed an action for infringement with respect to one patent against Pfizer and BioNTech,” a spokesperson for BioNTech told The Epoch Times in an email. The company declined further comment.

“Moderna is aware of the litigation and will defend ourselves against these claims,” a spokesman for Moderna told The Epoch Times via email.

Pfizer did not return an inquiry.

In a third lawsuit, lodged in federal court in New Jersey, Bayer said Johnson & Johnson also infringed on a patent with its COVID-19 vaccine, which did not utilize mRNA.

That complaint said Johnson & Johnson’s vaccine, which delivered DNA to a recipient’s cells to trigger protection, would not have been effective without the patented sequence and template that Bayer developed and patented.

Johnson & Johnson’s vaccine was withdrawn from the market in 2023. Johnson & Johnson did not respond to a request for comment.

The new complaints are the latest over the COVID-19 vaccines. Other suits have involved Pfizer and Moderna, including a suit brought by Moderna against Pfizer.

A court in England ruled in 2024 that Pfizer infringed on a Moderna patent.

Tyler Durden
Thu, 01/08/2026 – 21:30

Tyler DurdenSource

Share:

Previus Post
US Control
Next Post
Interpello: Regime

Leave a comment

Cancel reply

Recent Posts

  • Independent assessment to support establishment of a Future Entity
  • Predisposizione, da parte dell’Agenzia delle entrate, delle bozze dei registri IVA, delle liquidazioni periodiche dell’IVA e della dichiarazione annuale dell’IVA di cui all’articolo 4 del decreto legislativo 5 agosto 2015, n. 127. Ulteriore estensione del periodo sperimentale stabilito con il provvedimento del Direttore dell’Agenzia delle entrate n. 183994 dell’8 luglio 2021 (provvedimento)
  • Istituzione delle causali contributo per il versamento, tramite modello F24, dei contributi all’INPS da destinare ad Enti Bilaterali (risoluzione n. 5)
  • Deadline for challenging your business rates valuation
  • Targeted financial support for aspiring social workers

Recent Comments

  1. validtheme on Digital Camera

Archives

  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025

Categories

  • Finance
  • internal news
  • Italy
  • Uncategorized
  • United Kingdom

Recent Posts

  • Independent assessment to support establishment of a Future Entity
    09 March, 2026Independent assessment to support
  • Predisposizione, da parte dell’Agenzia delle entrate, delle bozze dei registri IVA, delle liquidazioni periodiche dell’IVA e della dichiarazione annuale dell’IVA di cui all’articolo 4 del decreto legislativo 5 agosto 2015, n. 127. Ulteriore estensione del periodo sperimentale stabilito con il provvedimento del Direttore dell’Agenzia delle entrate n. 183994 dell’8 luglio 2021 (provvedimento)
    09 March, 2026Predisposizione, da parte dell’Agenzia
  • 09 March, 2026Istituzione delle causali contributo
  • Deadline for challenging your business rates valuation
    09 March, 2026Deadline for challenging your

Tags

Blue%20Finessence

Excellence decisively nay man yet impression for contrasted remarkably. There spoke happy for you are out. Fertile how old address did showing.

Contact Info

  • Address:CEO Blue FinEssence Ltd Piccadilly Circus 126 London
  • Email:director@bluefinessence.com
  • Phone:004407784915057

Copyright 2024 Bluefinessence. All Rights Reserved by Bluefinessence

  • About Us
  • Our Services